Palvella Therapeutics, Inc.
PVLA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $26,712 | $21,556 | $15,816 | $13,716 |
| - Cash | $83,602 | $7,350 | $16,053 | $117,764 |
| + Debt | $0 | $0 | $0 | $14,890 |
| Enterprise Value | -$56,890 | $14,206 | -$237 | -$89,158 |
| Revenue | $0 | $0 | $25,902 | $31,418 |
| % Growth | – | -100% | -17.6% | – |
| Gross Profit | $0 | $0 | $23,122 | $29,050 |
| % Margin | – | – | 89.3% | 92.5% |
| EBITDA | -$13,117 | $18,691 | -$30,497 | -$43,370 |
| % Margin | – | – | -117.7% | -138% |
| Net Income | -$17,434 | $18,691 | -$33,277 | -$45,738 |
| % Margin | – | – | -128.5% | -145.6% |
| EPS Diluted | -7.83 | 14.74 | -29.61 | -56.69 |
| % Growth | -153.1% | 149.8% | 47.8% | – |
| Operating Cash Flow | -$10,840 | -$13,703 | -$14,840 | -$7,660 |
| Capital Expenditures | $0 | $0 | $0 | -$949 |
| Free Cash Flow | -$10,840 | -$13,703 | -$14,840 | -$8,609 |